← Leaderboards
Shikhar Mehrotra
Lipo-Immuno Tech, Llc
$2,618,726
Attributed
$2,618,726
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2020–24$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,618,726 · 3
By mechanism
R42$2,000,000 · 1
R41$618,726 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsPhenotypeImmunotherapyIn Vivo ModelNeoplastic CellPhase I Clinical TrialsEpitopesImmunosuppressionCancer PatientIn VivoMemoryMetabolicCell DeathPathway InteractionsCellsAdoptive Cell TransfersExhibitsGenerationsChronicCommercializationCostAntigensAdoptive TransferPredisposition
Grant awards (4)
Programming Metabolically Fit TILs for Immunotherapy$1,000,000
R42 · FY2024 · CA · contact PI
Programming Metabolically Fit TILs for Immunotherapy$1,000,000
R42 · FY2023 · CA · contact PI
Increasing Thiols for Improving T cell Immunotherapy$394,167
R41 · FY2022 · CA · contact PI
Programming Metabolically Fit TILs for Immunotherapy$224,559
R41 · FY2020 · CA · contact PI